Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity

Figure 5 Aspirin can inhibit hepatocellular carcinoma tumor growth and epithelial-mesenchymal transition by inhibiting platelet activity. A and B: Cytotoxicity analysis of the IC50 of aspirin in HepG2 and SMMC-7721 cells; C and D: CCK8 analysis of the effects of different concentrations of aspirin on the proliferation of hepatocellular carcinoma (HCC) cells; E and F: CCK8 analysis to detect the effect of platelets and aspirin on the proliferation of HCC cells; G and H: Real time polymerase chain reaction was used to detect the effects of platelets and aspirin on epithelial-mesenchymal transition in HCC cells. The figure shows the mean ± SD of the experimental results, with asterisks denoting significant differences between the two groups (^aP < 0.05, ^bP < 0.01, ^cP < 0.001). NC: Negative control; PPP: Platelet plasma; PRP: Platelet-rich plasma; FBS: Fetal bovine serum; PLT: Platelets.